Market Overview:
The global nifedipine market is expected to grow at a CAGR of 5.5% from 2018 to 2030. The growth in the market can be attributed to the increasing prevalence of cardiovascular diseases, rising geriatric population, and growing awareness about the benefits of nifedipine therapy. By type, the global nifedipine market is segmented into nifedipine controlled release tablets and nifedipine extended action tablets. The controlled release tablets segment is expected to grow at a higher CAGR than the extended action tablets segment during the forecast period. By application, the primary pulmonary hypertension (PPH) segment accounted for majority share of revenue in 2017 and is projected to maintain its dominance during the forecast period owing to high prevalence rate of PPH across regions. However, heart failure (HF) is also anticipated to be one of fastest-growing segments due to increasing incidence rates HF globally.
Product Definition:
Nifedipine is a calcium channel blocker used to treat high blood pressure and angina (chest pain). It relaxes the muscles of your heart and widens the arteries, which allows more blood to flow through them.
Nifedipine Controlled Release Tablets:
Nifedipine Controlled release tablets are used for the treatment of heart failure and pre-eclampsia. It works by opening up the blood vessels to allow more blood flow which ultimately reduces the workload on the heart. The drug was developed as a non-surgical method of treating hypertension, which is one of the most common diseases in developed countries like U.S., Canada, Germany etc.
Nifedipine Extended Action Tablets:
Nifedipine is used to treat heart failure, pulmonary edema, and hypertension. The extended-release (ER) tablets of nifedipine are used in the treatment of heart failure and hypertension. Heart failure is characterized by the inability of the heart to pump sufficient blood volume with an adequate supply of oxygenated blood.
Application Insights:
Primary pulmonary hypertension was the largest application segment in 2017 and is expected to continue its dominance over the forecast period. The high prevalence of primary pulmonary hypertension across various regions, such as North America and Europe, is anticipated to contribute towards steady growth of this segment during the forecast period.
The others segment includes cardiovascular diseases, kidney disease and urinary tract infections. Increasing cases of cardiovascular diseases are projected to drive demand for nifedipine globally over the forecast period. According to a study conducted by NCBI in 2015, it was estimated that around 1 death occurs due to coronary heart disease every 40 seconds globally with more than 600k deaths annually due to CHD in U.S., China & India combined while about 300k deaths occur dueS each year globally owingto stroke which accounts for about 80% of all strokes occurrences worldwide along with other non-communicable diseases (NCDs).
Regional Analysis:
North America dominated the global market in 2017. This is attributed to favorable reimbursement policies, rising prevalence of hypertension, and increasing awareness about drug therapies. Moreover, growing target population base and high healthcare expenditure are also expected to drive the regional market over the forecast period.
Asia Pacific is expected to witness lucrative growth during the forecast period owing to improving economic conditions in emerging countries such as India & China and government initiatives for a cashless society. These factors are anticipated to boost pharmaceutical demand across this region over the next eight years ending on 2030 AD (calendar year). Furthermore, rapidly expanding medical tourism industry due to lower treatment costs coupled with an increase in patient disposable income will further propel product demand across Asia Pacific during this timeframe ending on 2030 AD (calendar year).
Growth Factors:
- Increasing prevalence of hypertension and other cardiovascular diseases: The global prevalence of hypertension is estimated to be around 1.13 billion in 2015 and is projected to reach 1.56 billion by 2025. This will create a large pool of patients who will require treatment, thereby driving the demand for nifedipine products.
- Rising geriatric population: The global geriatric population (aged 65 years or above) is expected to grow from 524 million in 2010 to nearly 1.5 billion by 2050, creating a large pool of patients with age-related health conditions such as hypertension and coronary artery disease that can be treated with nifedipine products.
Scope Of The Report
Report Attributes
Report Details
Report Title
Nifedipine Market Research Report
By Type
Nifedipine Controlled Release Tablets, Nifedipine Extended Action Tablets
By Application
Primary Pulmonary Hypertension, Heart Failure, Others
By Companies
Bayer, Actavis, Teva, Pfizer, Shyndec, Honglin, Huanghai, Yabao
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
140
Number of Tables & Figures
98
Customization Available
Yes, the report can be customized as per your need.
Global Nifedipine Market Report Segments:
The global Nifedipine market is segmented on the basis of:
Types
Nifedipine Controlled Release Tablets, Nifedipine Extended Action Tablets
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Primary Pulmonary Hypertension, Heart Failure, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Bayer
- Actavis
- Teva
- Pfizer
- Shyndec
- Honglin
- Huanghai
- Yabao
Highlights of The Nifedipine Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Nifedipine Controlled Release Tablets
- Nifedipine Extended Action Tablets
- By Application:
- Primary Pulmonary Hypertension
- Heart Failure
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Nifedipine Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Nifedipine is a medication used to treat high blood pressure. It works by relaxing the blood vessels and reducing the amount of blood that flows through them. This helps to lower your blood pressure.
Some of the key players operating in the nifedipine market are Bayer, Actavis, Teva, Pfizer, Shyndec, Honglin, Huanghai, Yabao.
The nifedipine market is expected to grow at a compound annual growth rate of 5.5%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Nifedipine Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Nifedipine Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Nifedipine Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Nifedipine Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Nifedipine Market Size & Forecast, 2018-2028
4.5.1 Nifedipine Market Size and Y-o-Y Growth
4.5.2 Nifedipine Market Absolute $ Opportunity
Chapter 5 Global Nifedipine Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Nifedipine Market Size Forecast by Type
5.2.1 Nifedipine Controlled Release Tablets
5.2.2 Nifedipine Extended Action Tablets
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Nifedipine Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Nifedipine Market Size Forecast by Applications
6.2.1 Primary Pulmonary Hypertension
6.2.2 Heart Failure
6.2.3 Others
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Nifedipine Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Nifedipine Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Nifedipine Analysis and Forecast
9.1 Introduction
9.2 North America Nifedipine Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Nifedipine Market Size Forecast by Type
9.6.1 Nifedipine Controlled Release Tablets
9.6.2 Nifedipine Extended Action Tablets
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Nifedipine Market Size Forecast by Applications
9.10.1 Primary Pulmonary Hypertension
9.10.2 Heart Failure
9.10.3 Others
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Nifedipine Analysis and Forecast
10.1 Introduction
10.2 Europe Nifedipine Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Nifedipine Market Size Forecast by Type
10.6.1 Nifedipine Controlled Release Tablets
10.6.2 Nifedipine Extended Action Tablets
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Nifedipine Market Size Forecast by Applications
10.10.1 Primary Pulmonary Hypertension
10.10.2 Heart Failure
10.10.3 Others
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Nifedipine Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Nifedipine Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Nifedipine Market Size Forecast by Type
11.6.1 Nifedipine Controlled Release Tablets
11.6.2 Nifedipine Extended Action Tablets
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Nifedipine Market Size Forecast by Applications
11.10.1 Primary Pulmonary Hypertension
11.10.2 Heart Failure
11.10.3 Others
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Nifedipine Analysis and Forecast
12.1 Introduction
12.2 Latin America Nifedipine Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Nifedipine Market Size Forecast by Type
12.6.1 Nifedipine Controlled Release Tablets
12.6.2 Nifedipine Extended Action Tablets
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Nifedipine Market Size Forecast by Applications
12.10.1 Primary Pulmonary Hypertension
12.10.2 Heart Failure
12.10.3 Others
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Nifedipine Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Nifedipine Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Nifedipine Market Size Forecast by Type
13.6.1 Nifedipine Controlled Release Tablets
13.6.2 Nifedipine Extended Action Tablets
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Nifedipine Market Size Forecast by Applications
13.10.1 Primary Pulmonary Hypertension
13.10.2 Heart Failure
13.10.3 Others
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Nifedipine Market: Competitive Dashboard
14.2 Global Nifedipine Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Bayer
14.3.2 Actavis
14.3.3 Teva
14.3.4 Pfizer
14.3.5 Shyndec
14.3.6 Honglin
14.3.7 Huanghai
14.3.8 Yabao
